But Schiffman said the clinical try is "well powered" to have a "reasonable possibility" of reaching statistical value on survival by the interim. However, he hedged a little. "We're very hysterical about the timeframe," he said, "but, I do want to something out that the terminal (results) always has a higher likeliness of success.
" Again, the decisive results aren't expected until next year sometime. The Dendreon breakout drew, by far, the fewest citizenry of the ones I've attended today. Nine investors/analysts profit me and a Dow Jones reporter. Read what you will into that. One of the attendees asked how much the drug, called Provenge, would cost.
Schiffman said, "It's not gonna be an budget-priced treatment." When pressed for a dollar play a part he only said it would suitable be priced in business with other romance biologics. The questioner threw out the device $20,000. "Probably above that," Schiffman said, adding that novelette biologics expense about twice that amount.
http://drug-purchase.info/blog/wp-content/plugins/s4/cache/dendreon.jpg
Presumably that would be for the uncensored three-infusion treatment. Let the countdown begin.
With respect to post: read
No comments:
Post a Comment